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  The emerging trend of multidrug resistance is becoming 
a major threat to community acquired and nosocomial 
infections, worldwide[1]. The carbapenems are used as 
last-source drugs because of increasing resistance against 
beta-lactam groups of antibiotics due to its excessive 
use to treat wide range of infections[2]. The resistance 
against carbapenem group of antibiotics has also emerged 
worldwide for at least one decade and has becoming a 
major public problem. The latest (metallo beta-lactamase) 
MBL, named NDM-1 (New Delhi Metallo beta lactamse) has 
been identified as novel class of carbapenemase found in 
enterobacteriaceae, first isolated from Swedish patient of 
Indian origin. He traveled to India and admitted in Ludhiana 
hospital in Punjab, later he was admitted to the hospital in 
New Delhi[3,4]. This was the first report of blaNDM-1 and the 
first report of MBL carriage among enterobacteriaceae from 
UK. NDM-1 carrying isolates confer resistance against all 
beta-lactamases except colistin and aztreonam[4]. In view 
of current situation we have developed a quick and easy 
detection of NDM producers in clinical isolates from site of 
infection. This method would be effective and economical 
for hospitals in developing countries where no huge funds 
are available for using sophisticated infrastructure to 
identify and detect these resistant markers.
  We have screened 100 clinical isolates from Aligarh 
hospital including (intensive care unit) ICU samples. These 
isolates were grown on (brain heart infusion) BHI broth 
and the cells were spread over Imipenem supplemented 
plates (Figure 1). Only carbapenem resistant strains were 
found to grow. Of 100, only two isolates (these were later 
confirmed as Klebsiella pneumoniae, data is not needed 
here) showed growth on the plates containing (IMP) 
imipenem (5 mg/L). Moreover, all the 100 isolates were 
grown on Mueller-Hinton agar (BD diagnostics, USA) for an 
Imipenem/EDTA disc potentiation test to detect production 
of carbapenemase[5]. The enlargement of inhibition zone 
was observed as >3.5 mm around the disk in the presence 
of IMP (10 毺g) + EDTA (10 毺L of 0.1 M) whereas, no 
zone was observed around the IMP disk alone. It is the 
indication of carbapenemase production as being inhibited 
by EDTA. A single colony was picked from each plate and 
streaked on Aztreonam (10 mg/L) supplemented plate. No 
growth was found on these plates.  A single colony from 
IMP-plate was suspended in 100 毺L of sterilized water 
(Figure 1) and was incubated at 95 曟 for 10 min followed 
by centrifugation at 8 000 g for 5 min.  Supernatant was 
used as template to perform PCR amplification using 
NDM-F, CATGCCGGGTTTCGGGGCAGTC and NDM-R, 
GAGCGACTTGGCCTTGCTGTCC primers with the PCR 
profile, each cycle of denaturation at 95 曟 for 30 s, 
annealing at 55 曟 for 30 s, and extension at 72 曟 for 1 min 
for 35 cycles. Both the isolates showed positive for presence 
of NDM-1. It was further confirmed by sequence analysis. 
The Etest MBL strip is one of the methods used for detecting 
metallo-b-lactamase (MBL) producers based on inhibition 
of MBL activity by EDTA[6] but it is not easily accessible 
for low income countries hospitals. Nordmann’s group in 
France used automated susceptibility testing by Vitek2 
(bioMe ´rieux) for screening NDM-producers followed by 
molecular characterization[7] and also this technique is not 
easily available in each hospital. Since efficient prevention 
of the spread of NDM-1 producers requires a quick and 
easy screening method that can detect NDM-1 producers as 
colonizers and thus our method is quick, easy as well as cost 
effective and can be affordable for any hospital infection 
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control setup. It is of utmost important to develop good 
laboratories services for surveillance and control measures. 
This study provides an easy and quick method for the 
detection of NDM variants among the clinical isolates and 
hence early prevention of NDM-producers in the community 
and hospital setting. Moreover, the method is cost effective 
for low income countries where emerging trends of NDM-1 
producers is always high due to poor hygiene conditions.
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Figure 1. Scheme for easy and quick detection of NDM producers in 
clinical samples.
Agarose gel showing DNA marker, two NDM-1 producers
(K. pneumoniae) from clinical isolates, Positive control and negative 
control. BHI (Brain Heart Infusion ), IMP (Imipenem).
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